1. Protein Tyrosine Kinase/RTK
  2. Ephrin Receptor

ALW-II-41-27 (Synonyms: Eph receptor tyrosine kinase inhibitor)

Cat. No.: HY-18007 Purity: 99.59%
Data Sheet SDS Handling Instructions

ALW-II-41-27 is a novel Eph receptor tyrosine kinase inhibitor, used for cancer treatment.

For research use only. We do not sell to patients.
ALW-II-41-27 Chemical Structure

ALW-II-41-27 Chemical Structure

CAS No. : 1186206-79-0

Size Price Stock Quantity
10 mM * 1 mL in DMSO $412 In-stock
5 mg $308 In-stock
10 mg $396 In-stock
50 mg $1067 In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

    ALW-II-41-27 purchased from MCE. Usage Cited in: Oncogene. 2017 Jun 5.

    C3-TAg cells are starved and stimulated for 0, 15 and 30 min with ephrin-A1-Fc (EphA2 ligand; 1 μg/mL) in the presence or absence of ALW-II-41-27 or NG-25 control. EphA2 is immunoprecipitated and products probed for tyrosine phosphorylation and EphA2. ALW-II-41-27 significantly reduces basal and ephrin-A1-Fc induced tyrosine phosphorylation.

    ALW-II-41-27 purchased from MCE. Usage Cited in: Nat Commun. 2017 Jun 6;8:15729.

    EphA2 immunoprecipitates prepared from MCF-7 cells expressing ectopic EphA2 are immunoblotted with anti-phosphotyrosine and anti-EphA2 antibody. The indicated samples are treated with recombinant human ephrin-A1 (500 ng/mL) for 20 min. Eight-hour pre-treatment with the EphA2 inhibitor ALW-II-41-27 (100 nM) suppressed ephrin-A1-induced EphA2 phosphorylation.

    Featured Recommendations

    Related Small Molecules:

    View MoreCollapse
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References

    Description

    ALW-II-41-27 is a novel Eph receptor tyrosine kinase inhibitor, used for cancer treatment.

    In Vitro

    ALW-II-41-27 inhibits Ba/F3 cells transformed with Tel fusions of EphA3, Kit, Fms, KDR, FLT1, FGR, Src, Lyn, Bmx, and Bcr-Abl with an EC50 below 500 nM. ALW-II-41-27 exhibits cross reactivity with Bcr-Abl. ALW-II-41-27 inhibits b-raf, CSF1R, DDR1, DDR2, EphA2, EphA5, EphA8, EphB1, EphB2, EphB3, Frk, Kit, Lck, p38α, p38β, PDGFRα, PDGFRβ, and Raf1 and many more demonstrating how introduction of the thiophene group can have a tremendous impact on kinase selectivity[1].

    References
    Preparing Stock Solutions
    Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
    1 mM 1.6456 mL 8.2279 mL 16.4558 mL
    5 mM 0.3291 mL 1.6456 mL 3.2912 mL
    10 mM 0.1646 mL 0.8228 mL 1.6456 mL
    References
    Molecular Weight

    607.69

    Formula

    C₃₂H₃₂F₃N₅O₂S

    CAS No.

    1186206-79-0

    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.

    Shipping

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    DMSO: ≥ 47 mg/mL

    ALW-II-41-27 is prepared in 10% 1-methyl-2-pyrrolidinone and 90% polyethylene glycol 300[2].

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    References

    Purity: 99.59%

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number

     

    Organization name *

    Country *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    ALW-II-41-27
    Cat. No.:
    HY-18007
    Quantity: